Search results
Alzheimer's drug development pipeline: Positive results, new insight on biomarkers position 2024 as...
Medical Xpress· 2 weeks agoOn the heels of newly FDA-approved drugs Aduhelm (aducanumab) in 2021 and Leqembi (lecanemab) in...
Medicare Says It Expects To Spend $3.5 Billion In 2025 On Alzheimer’s Drug Leqembi, But This Is...
Forbes· 4 days agoTo arrive at the estimates, CMS considered a number of public sources, including a paper in the...